- Xarelto Dangers Investigated in Canada
- October 26, 2015
- Law Firm: Waters Kraus LLP - Dallas Office
- The Canadian government has recently initiated a probe into the dangers associated with the blood thinner Xarelto (rivaroxaban). In July 2011, the U.S. Food & Drug Administration (FDA) approved the anti-clotting agent for patients receiving knee and hip replacements, to prevent strokes. Later the same year, the FDA expanded its approval of the prescription drug to include patients with irregular heartbeat, known as atrial fibrillation. Millions of Americans are now taking Xarelto and the drug is a huge profit center for its makers, Bayer AG and Janssen Pharmaceuticals, Johnson & Johnson's pharmaceutical unit.
Health Canada Report Reveals Possible Xarelto Liver Injuries
Canadian health regulators reportedly are looking into liver injuries that doctors suspect are caused by Xarelto usage. On August 26, a Health Canada safety review document was released, which reveals that 61 Canadians have reported liver injuries after taking Xarelto. The World Health Organization (WHO) has received reports concerning 431 patients with injury to the liver after taking the prescription. In 23 cases, the patient was taking no drugs other than Xarelto. The Health Canada report indicates that the government there will monitor the situation to reach a decision about the Xarelto health risks. Xarelto users are also encouraged to report liver injuries to Health Canada.
Meanwhile, south of the Canadian border in the United States, Xarelto lawsuits are on the rise. More and more people continue to suffer drug injuries, such as uncontrollable bleeding incidents as a result of their usage of Xarelto. The anticoagulant is used by many as a replacement for warfarin, for decades the blood thinner of choice. When a patient is using warfarin, if an internal bleeding emergency occurs, doctors can stop it by administering vitamin K, which makes the blood clot. But with Xarelto, there is no antidote to stop the bleeding.